院前创伤汇编:创伤中的氨甲环酸——NAEMSP、ACEP与ACS-COT联合立场声明与资源文件
该联合立场声明由NAEMSP、ACEP与ACS-COT制定,基于结构化文献综述更新2016年版院前氨甲环酸使用指南。推荐对临床有失血性休克征象的成人创伤患者,在挽救生命干预后、伤后3小时内给予院前氨甲环酸,可能降低死亡率;院前给药似乎安全,血栓栓塞事件或癫痫风险低。理想剂量、速率和途径尚未确定,当前证据支持1克IV/IO后院内1克/8小时输注,或2克IV/IO输注或缓慢推注。儿童创伤患者院前氨甲环酸作用尚未研究,标准化剂量未建立;如使用应在伤后3小时内给药。院前给药应明确告知接收医疗人员,以避免重复给药并促进适当监测。
要点
- 对临床有失血性休克征象的成人创伤患者,在挽救生命干预后给予院前氨甲环酸可能降低死亡率。
- 院前氨甲环酸给药似乎安全,血栓栓塞事件或癫痫风险低。
- 成人创伤失血性休克:可用1克IV/IO后院内1克/8小时输注,或2克IV/IO输注或缓慢推注;理想剂量、速率和途径尚未确定。
- 如用于成人创伤患者,应给予临床有失血性休克征象者,且不晚于伤后3小时;无证据支持超过此时限或无临床显著出血者启动氨甲环酸改善结局。
- 院前氨甲环酸给药应明确告知接收医疗人员,以促进适当监测并避免重复给药。
适用人群与场景
- 成人创伤患者,临床有失血性休克征象,在挽救生命干预后接受院前氨甲环酸。
- 儿童创伤患者临床有失血性休克征象时院前氨甲环酸的作用尚未研究,标准化剂量尚未建立。
诊断标准与关键阈值
- 如用于成人创伤患者,应给予临床有失血性休克征象者,且不晚于伤后3小时。
- 无证据支持超过伤后3小时或无临床显著出血者启动氨甲环酸改善临床结局。
处置流程与药物剂量
- 成人创伤失血性休克:当前证据提示EMS机构可给予1克IV/IO剂量(随后院内1克输注8小时),或2克IV/IO剂量作为输注或缓慢推注。
- 儿童创伤患者如使用氨甲环酸,应在伤后3小时内给药;标准化剂量尚未建立。
- 院前氨甲环酸给药应明确告知接收医疗人员,以促进适当监测并避免重复给药。
- 应由EMS医师领导的多学科团队(包括EMS临床人员、急诊医师和创伤外科医师)负责制定质量改进项目,评估院前氨甲环酸给药的方案依从性并识别临床并发症。
研究设计与关键结果
- 该立场声明基于结构化文献综述制定,更新2016年NAEMSP、ACS-COT与ACEP发布的院前创伤患者氨甲环酸使用指南。
- 院前氨甲环酸给药可能降低成人创伤失血性休克患者在挽救生命干预后给药的死亡率。
- 院前氨甲环酸给药似乎安全,血栓栓塞事件或癫痫风险低。
- 成人创伤失血性休克院前氨甲环酸的理想剂量、速率和途径尚未确定。
- 儿童创伤患者临床有失血性休克征象时院前氨甲环酸的作用尚未研究,标准化剂量尚未建立。
证据类型、等级与局限
- 证据类型:NAEMSP、ACEP与ACS-COT联合立场声明与资源文件,基于结构化文献综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对临床有失血性休克征象的成人创伤患者,可在挽救生命干预后、伤后3小时内给予院前氨甲环酸;无临床显著出血或超过伤后3小时者无证据支持启动氨甲环酸改善结局。
- 成人创伤失血性休克院前氨甲环酸可用1克IV/IO后院内1克/8小时输注,或2克IV/IO输注或缓慢推注;理想剂量、速率和途径尚未确定。
- 儿童创伤患者院前氨甲环酸作用尚未研究、标准化剂量未建立;如使用应在伤后3小时内给药。
- 院前给予氨甲环酸后应明确告知接收医疗人员,以避免重复给药并促进适当监测。
- 应由EMS医师领导的多学科团队制定质量改进项目,评估方案依从性并识别临床并发症。
指南或共识出处
- Prehospital Trauma Compendium: Tranexamic Acid in Trauma - A Joint Position Statement and Resource Document of NAEMSP, ACEP, and ACS-COT(Prehosp Emerg Care)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Prehospital use of tranexamic acid (TXA) has grown substantially over the past decade despite contradictory evidence supporting its widespread use. Since the previous guidance document on the prehospital use of TXA for injured patients was published by the National Association of Emergency Medical Services Physicians (NAEMSP), the American College of Surgeons Committee on Trauma (ACS-COT), and the American College of Emergency Physicians (ACEP) in 2016, new research has investigated outcomes of patients who receive TXA in the prehospital setting. To provide updated evidence-based guidance on the use of intravenous TXA for injured patients in the EMS setting, we performed a structured literature review and developed the following recommendations supported by the evidence summarized in the accompanying resource document.
Prehospital TXA administration may reduce mortality in adult trauma patients with hemorrhagic shock when administered after lifesaving interventions.Prehospital TXA administration appears safe, with low risk of thromboembolic events or seizure.The ideal dose, rate, and route of prehospital administration of TXA for adult trauma patients with hemorrhagic shock has not been determined. Current evidence suggest EMS agencies may administer either a 1-gram IV/IO dose (followed by a hospital-based 1-gram infusion over 8 hours), or a 2-gram IV/IO dose as an infusion or slow push.Prehospital TXA administration, if used for adult trauma patients, should be given to those with clinical signs of hemorrhagic shock and no later than 3 hours post-injury. There is no evidence to date to suggest improved clinical outcomes from TXA initiation beyond this time or in those without clinically significant bleeding.The role of prehospital TXA in pediatric trauma patients with clinical signs of hemorrhagic shock has not been studied and standardized dosing has not been established. If used, it should be given within 3 hours of injury.Prehospital TXA administration, if used, should be clearly communicated to receiving healthcare professionals to promote appropriate monitoring and to avoid duplicate administration(s).A multidisciplinary team, led by EMS physicians, that includes EMS clinicians, emergency physicians, and trauma surgeons should be responsible for developing a quality improvement program to assess prehospital TXA administration for protocol compliance and identification of clinical complications.
参考来源
- Barrett WJ, Kaucher KA, Orpet RE, et al. Prehospital Trauma Compendium: Tranexamic Acid in Trauma - A Joint Position Statement and Resource Document of NAEMSP, ACEP, and ACS-COT. Prehosp Emerg Care. 2025. PMID: 40323259. doi:10.1080/10903127.2025.2497056
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。